TY - JOUR AU - Sorlie, T. AU - Perou, C. M. AU - Tibshirani, R. AU - Aas, T. AU - Geisler, S. AU - Johnsen, H. PY - 2001 DA - 2001// TI - Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications JO - Proc Natl Acad Sci VL - 98 UR - https://doi.org/10.1073/pnas.191367098 DO - 10.1073/pnas.191367098 ID - Sorlie2001 ER - TY - BOOK AU - Stenger, M. PY - 2014 DA - 2014// TI - Incidence of breast Cancer according to joint hormone receptor and HER2 status differs according to race/ethnicity and other factors - the ASCO post ID - Stenger2014 ER - TY - BOOK PY - 2017 DA - 2017// TI - Managing advanced breast cancer ID - ref3 ER - TY - STD TI - Howlader N, Altekruse S, Li C, Chen V, Clarke C, Ries L, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5). https://doi.org/10.1093/jnci/dju055. ID - ref4 ER - TY - JOUR AU - Cardoso, F. AU - Senkus, E. AU - Costa, A. AU - Papadopoulos, E. AU - Aapro, M. AU - André, F. PY - 2018 DA - 2018// TI - 4th ESO–ESMO international consensus guidelines for advanced breast Cancer (ABC 4)† JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdy192 DO - 10.1093/annonc/mdy192 ID - Cardoso2018 ER - TY - STD TI - Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018; [cited 2019 Jun 6]; Available from: https://ascopubs.org/doi/pdf/10.1200/JCO.2018.79.2697. UR - https://ascopubs.org/doi/pdf/10.1200/JCO.2018.79.2697 ID - ref6 ER - TY - BOOK PY - 2018 DA - 2018// TI - Clinical practice guidelines in oncology - breast [internet]. NCCN ID - ref7 ER - TY - JOUR AU - Beck, J. T. AU - Hortobagyi, G. N. AU - Campone, M. AU - Lebrun, F. AU - Deleu, I. AU - Rugo, H. S. PY - 2014 DA - 2014// TI - Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2 JO - Breast Cancer Res Treat VL - 143 UR - https://doi.org/10.1007/s10549-013-2814-5 DO - 10.1007/s10549-013-2814-5 ID - Beck2014 ER - TY - JOUR AU - Xu, H. AU - Yu, S. AU - Liu, Q. AU - Yuan, X. AU - Mani, S. AU - Pestell, R. G. PY - 2017 DA - 2017// TI - Recent advances of highly selective CDK4/6 inhibitors in breast cancer JO - J Hematol OncolJ Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0467-2 DO - 10.1186/s13045-017-0467-2 ID - Xu2017 ER - TY - JOUR AU - Hortobagyi, G. N. AU - Stemmer, S. M. AU - Burris, H. A. AU - Yap, Y. S. AU - Sonke, G. S. AU - Paluch-Shimon, S. PY - 2017 DA - 2017// TI - Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC) JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.1038 DO - 10.1200/JCO.2017.35.15_suppl.1038 ID - Hortobagyi2017 ER - TY - JOUR AU - Finn, R. S. AU - Crown, J. P. AU - Ettl, J. AU - Schmidt, M. AU - Bondarenko, I. M. AU - Lang, I. PY - 2016 DA - 2016// TI - Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 JO - Breast Cancer Res VL - 18 UR - https://doi.org/10.1186/s13058-016-0721-5 DO - 10.1186/s13058-016-0721-5 ID - Finn2016 ER - TY - JOUR AU - Turner, N. C. AU - Slamon, D. J. AU - Ro, J. AU - Bondarenko, I. AU - Im, S. -. A. AU - Masuda, N. PY - 2018 DA - 2018// TI - Overall survival with Palbociclib and Fulvestrant in advanced breast Cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1810527 DO - 10.1056/NEJMoa1810527 ID - Turner2018 ER - TY - JOUR AU - Dickler, M. N. AU - Tolaney, S. M. AU - Rugo, H. S. AU - Cortés, J. AU - Diéras, V. AU - Patt, D. PY - 2017 DA - 2017// TI - MONARCH 1, a phase II study of Abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast Cancer JO - Clin Cancer Res Off J Am Assoc Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-0754 DO - 10.1158/1078-0432.CCR-17-0754 ID - Dickler2017 ER - TY - JOUR AU - Slamon, D. J. AU - Neven, P. AU - Chia, S. AU - Fasching, P. A. AU - Laurentiis, M. AU - Im, S. -. A. PY - 2018 DA - 2018// TI - Phase III randomized study of Ribociclib and Fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast Cancer: MONALEESA-3 JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.78.9909 DO - 10.1200/JCO.2018.78.9909 ID - Slamon2018 ER - TY - STD TI - Overview | Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | Guidance | NICE [Internet]. [cited 2019 May 9]. Available from: https://www.nice.org.uk/guidance/ta495 UR - https://www.nice.org.uk/guidance/ta495 ID - ref15 ER - TY - STD TI - Overview | Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | Guidance | NICE [Internet]. [cited 2019 May 9]. Available from: https://www.nice.org.uk/guidance/ta496 UR - https://www.nice.org.uk/guidance/ta496 ID - ref16 ER - TY - STD TI - Overview | Everolimus with exemestane for treating advanced breast cancer after endocrine therapy | Guidance | NICE [Internet]. [cited 2019 May 9]. Available from: https://www.nice.org.uk/guidance/ta421 UR - https://www.nice.org.uk/guidance/ta421 ID - ref17 ER - TY - STD TI - NHS England » About information governance [Internet]. [cited 2018 Dec 13]. Available from: https://www.england.nhs.uk/ig/about/ UR - https://www.england.nhs.uk/ig/about/ ID - ref18 ER - TY - JOUR AU - Lobbezoo, D. J. A. AU - Kampen, R. J. W. AU - Voogd, A. C. AU - Dercksen, M. W. AU - Berkmortel, F. AU - Smilde, T. J. PY - 2016 DA - 2016// TI - In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands breast Cancer consortium JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdv544 DO - 10.1093/annonc/mdv544 ID - Lobbezoo2016 ER - TY - JOUR AU - D’Alonzo, A. AU - Bighin, C. AU - Puglisi, F. AU - DeLaurentiis, M. AU - Fontana, A. AU - Pugliese, P. PY - 2018 DA - 2018// TI - Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): Results of a multicentric Italian observational study JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.e13053 DO - 10.1200/JCO.2018.36.15_suppl.e13053 ID - D’Alonzo2018 ER - TY - JOUR AU - Swallow, E. AU - Zhang, J. AU - Thomason, D. AU - Tan, R. -. D. AU - Kageleiry, A. AU - Signorovitch, J. PY - 2014 DA - 2014// TI - Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012 JO - Curr Med Res Opin VL - 30 UR - https://doi.org/10.1185/03007995.2014.908829 DO - 10.1185/03007995.2014.908829 ID - Swallow2014 ER - TY - JOUR AU - Watanabe, J. AU - Hayashi, T. AU - Tadokoro, Y. AU - Nishimura, S. AU - Takahashi, K. PY - 2017 DA - 2017// TI - Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution JO - Breast Cancer Res Treat VL - 166 UR - https://doi.org/10.1007/s10549-017-4478-z DO - 10.1007/s10549-017-4478-z ID - Watanabe2017 ER - TY - JOUR AU - Lobbezoo, D. J. A. AU - Kampen, R. J. W. AU - Voogd, A. C. AU - Dercksen, M. W. AU - Berkmortel, F. AU - Smilde, T. J. PY - 2015 DA - 2015// TI - Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? JO - Br J Cancer VL - 112 UR - https://doi.org/10.1038/bjc.2015.127 DO - 10.1038/bjc.2015.127 ID - Lobbezoo2015 ER - TY - JOUR AU - O’Leary, B. AU - Finn, R. S. AU - Turner, N. C. PY - 2016 DA - 2016// TI - Treating cancer with selective CDK4/6 inhibitors JO - Nat Rev Clin Oncol VL - 13 UR - https://doi.org/10.1038/nrclinonc.2016.26 DO - 10.1038/nrclinonc.2016.26 ID - O’Leary2016 ER - TY - JOUR AU - Rodon, J. AU - Dienstmann, R. AU - Serra, V. AU - Tabernero, J. PY - 2013 DA - 2013// TI - Development of PI3K inhibitors: lessons learned from early clinical trials JO - Nat Rev Clin Oncol VL - 10 UR - https://doi.org/10.1038/nrclinonc.2013.10 DO - 10.1038/nrclinonc.2013.10 ID - Rodon2013 ER - TY - JOUR AU - Xi, J. AU - Oza, A. AU - Thomas, S. AU - Ademuyiwa, F. AU - Weilbaecher, K. AU - Suresh, R. PY - 2019 DA - 2019// TI - Retrospective analysis of treatment patterns and effectiveness of Palbociclib and subsequent regimens in metastatic breast Cancer JO - J Natl Compr Cancer Netw JNCCN VL - 17 UR - https://doi.org/10.6004/jnccn.2018.7094 DO - 10.6004/jnccn.2018.7094 ID - Xi2019 ER - TY - JOUR AU - Bonotto, M. AU - Gerratana, L. AU - Maio, M. D. AU - Angelis, C. D. AU - Cinausero, M. AU - Moroso, S. PY - 2017 DA - 2017// TI - Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis JO - Breast VL - 31 UR - https://doi.org/10.1016/j.breast.2016.10.021 DO - 10.1016/j.breast.2016.10.021 ID - Bonotto2017 ER - TY - JOUR AU - Pérol, D. AU - Robain, M. AU - Arveux, P. AU - Mathoulin-Pélissier, S. AU - Chamorey, E. AU - Asselain, B. PY - 2019 DA - 2019// TI - The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the epidemiological strategy and medical economics (ESME) JO - BMJ Open VL - 9 UR - https://doi.org/10.1136/bmjopen-2018-023568 DO - 10.1136/bmjopen-2018-023568 ID - Pérol2019 ER -